Palazestrant in the clinic.

Our lead investigational drug, palazestrant (OP-1250), is a novel oral compound developed to completely antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal.

Our pipeline

Indication
  • Discovery
  • Non-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration
Palazestrant (OP-1250) - ER+/HER2- Metastatic Breast Cancer

1st line combo with CDK 4/6i ribociclib

In Planning Opera Image
phase 3

2/3 line monotherapy

phase 3

Combo therapy with CDK4/6i ribociclib

In Collaboration with novartis logo
phase 2

Combo therapy with CDK4/6i palbociclib

In Collaboration with Pfizer Logo
phase 2

Combo therapy with PI3Ki alpelisib with PIK3CA mutated

In Collaboration with novartis logo
phase 1

Combo therapy with mTOR inhibitor everolimus

phase 1
OP-3136 KAT6 Inhibitor - Oncology

ER+/HER2+ metastatic breast cancer/castrate-resistant prostate/lung cancer

nonclinical

Clinical trials

Palazestrant (OP-1250) is currently in development as a treatment for ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), in both monotherapy and combination settings. Learn more about our Phase 3 trial, OPERA-01, investigating palazestrant compared to a common therapy.